In addition, more than 30 clinical trials were conducted in several cancers with colony-stimulating factor-1 receptor (CSF1R) inhibitors or CCR2 inhibitors: AMG 820 [302], LY3022855 ((NCT02265536; Immune PD reported, no efficacy) [303], emactuzumab (RG7155), cabiralizumab [304], lacnotuzumab (MCS110) [305], ARRY-382 ((NCT02880371; combination tolerated but limited efficacy) [305], BLZ945 [306], pexidartinib [307] and edicotinib [308]. The gene discussed is CSF1R; the disease is cancer.